• CA800-PR, Golgi Stress, and PR Suppression

  2026-10-19

  The cited Theranostics study presents CA800-PR as a tumor-targeted near-infrared heptamethine cyanine dye that was associated with Golgi fragmentation, progesterone-receptor suppression, apoptosis, and immune changes in MCF-7 models. Its most important contribution is a proposed connection between organelle stress and endocrine signaling, but the evidence remains preclinical and does not establish clinical efficacy or demonstrate that Golgi-Tracker Green reproduces CA800-PR biology.

• Saracatinib (AZD0530): Scope of the Evidence

  2026-10-19

  The APExBIO catalog identifies Saracatinib (AZD0530; SKU A2133) as a dual Src-family kinase and Abl inhibitor, reporting biochemical potency against c-Src and v-Abl and describing downstream effects on proliferation, migration, signaling, and xenograft growth. These claims provide a mechanistic and measurement framework, but the available product information does not identify an identity-matched research paper, study size, comparator, uncertainty estimate, or independently verifiable outcome dataset. The evidence therefore supports a proportionate cancer-biology overview rather than conclusions about clinical efficacy or general biological activity.

• 2X HyperFusion: Claims, Mechanism, and Boundaries

  2026-10-18

  The 2X HyperFusion High-Fidelity Master Mix is documented by APExBIO as a premixed PCR reagent containing a fusion proofreading polymerase, optimized buffer components, and dNTPs. Its stated architecture supports a plausible mechanism for increased fidelity and processivity, while reported comparisons with Taq and Pfu, amplification-length limits, speed, and blunt-end formation remain supplier claims without identity-matched research evidence, assay details, or independent validation.

• Cyclopamine in PTC: What the Evidence Shows

  2026-10-17

  Recent work links APOC1 expression with aggressive papillary thyroid carcinoma and identifies cyclopamine as a candidate Hedgehog signaling inhibitor for this context. The study reported reduced proliferation, greater apoptosis, and suppressed tumor growth in cellular and mouse models, with stronger effects after APOC1 depletion. However, the evidence remains model-specific: the computational nomination does not prove direct APOC1 targeting, the animal model lacked a functional immune system, and no clinical efficacy or human safety conclusion follows. Broader claims about cyclopamine in breast, colorectal, or developmental models should be treated as separate evidence streams rather than interchangeable validation.

• Nocodazole and the Cellular Entry of Spiroplasma

  2026-10-16

  Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters and affects an invertebrate cell model. Their inhibitor-based evidence implicated clathrin-mediated endocytosis, macropinocytosis, actin filaments, and microtubules, while the cytotoxicity and pharmacological specificity of the system limit how directly these findings can be generalized to crustacean tissues.

• Mifepristone, Receptor Context, and Evidence Boundaries

  2026-10-16

  Published work on androgen-receptor heterogeneity provides a useful framework for interpreting context-dependent drug response, but it does not establish Mifepristone or RU486 activity in prostate cancer. The strongest supplied evidence concerns AR-defined castration-resistant prostate cancer models, whereas the supplied product information presents broader progesterone-receptor, oncology, reproductive, and fibroid claims without linked primary-study details. The central unresolved issue is whether observations about AR state can be transferred to progesterone-receptor antagonism without direct receptor-matched comparisons.

• AT13387: A Source-Bounded Hsp90 Overview

  2026-10-15

  AT13387 is described by APExBIO as a synthetic, orally bioavailable small-molecule Hsp90 inhibitor with high-affinity binding and reported activity in A375 melanoma cells. The available evidence is limited to supplier-provided identity, mechanism, potency, and pharmacokinetic claims; it does not establish independent efficacy, selectivity, clinical benefit, or generalizability across tumor models.

• DRB: What the Product Record Supports

  2026-10-15

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB; SKU C4798) is described by APExBIO as a transcriptional elongation inhibitor that acts through several cyclin-dependent kinases associated with RNA polymerase II carboxy-terminal-domain regulation. The available evidence is a supplier description rather than an identity-matched research article, so its reported potency values and cellular or antiviral effects should be treated as assay-specific claims with limited independent validation in this evidence set.

• HLY78 and the Limits of Wnt Translational Evidence

  2026-10-14

  HLY78 is described as a ligand-dependent Wnt/β-catenin pathway modulator, while a 2024 mouse study links SFRP1 loss, neutrophil infiltration, and fibrosis in oral submucous fibrosis. These findings provide research context but do not establish that HLY78 treats fibrosis or reproduce the effects of SFRP1.

• Dovitinib and CircRHOBTB3: Evidence Gaps

  2026-10-13

  The available evidence does not provide a direct comparison between Dovitinib (TKI-258) and the circRHOBTB3–NONO–MAOA mechanism reported in metastatic prostate cancer. The published study supports a tumor-suppressive role for circRHOBTB3 in prostate-cancer models, while the supplier description presents Dovitinib as a multitargeted receptor tyrosine kinase research compound. These evidence streams differ in disease context, biological level and provenance, limiting cross-study interpretation.

• MLN4924 and Gossypol: Evidence Gaps

  2026-10-13

  The supplied literature supports distinct mechanistic interpretations for MLN4924 and gossypol, but it does not establish a direct, head-to-head comparison. The main evidence gap concerns whether differences in target level, assay context, selectivity, and cellular response can explain their reported effects across models.

• Saracatinib and Reelin–SFK Evidence

  2026-10-12

  A 2021 PNAS mouse study links intact Reelin–Apoer2–Src-family-kinase signaling with ketamine-associated synaptic and behavioral effects. The findings support a mechanistic hypothesis about baseline NMDA-receptor function, but they do not show that Saracatinib (AZD0530) was used in the study or that its cancer-biology profile predicts antidepressant activity.

• PDX1, m6A, and Pancreatic Agenesis

  2026-10-12

  Zhang et al. report a rare cynomolgus macaque model linking PDX1 mutation, pancreatic agenesis, and altered m6A methylation. The findings are notable but preliminary because they derive from three animals, with only one developing a pancreas suitable for extensive molecular analysis, and from organoid rescue studies that do not establish clinical causality.

• PF-562271 HCl in Cancer Immunology

  2026-10-10

  PF-562271 HCl offers a selective pharmacological lens for studying how FAK/Pyk2 signaling may intersect with radiotherapy, immune checkpoints, and tumor microenvironment biology. This article connects the compound’s reported properties with the 2025 Cancer Letters study while clearly separating established findings from testable interpretation.

• Nocodazole: Mechanism, Evidence, and Research Limits

  2026-10-09

  Nocodazole is a reversible microtubule polymerization inhibitor that perturbs β-tubulin-dependent assembly and microtubule dynamics. In a peer-reviewed Drosophila S2-cell study, nocodazole-associated cytoskeletal disruption reduced intracellular Spiroplasma eriocheiris, but the result did not by itself identify a pathogen-specific target or prove a single entry mechanism.

554 records 1/37 page Next 12345 下5页 Last page